High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias

Annals of Hematology

Volumn 82, Issue 8, 2003, Pages 476-480

  Petti, M C ^a   Tafuri, A ^b   Latagliata, R ^b   Aloe Spiriti, M A ^b   Montefusco, E ^b   Mancini, M ^b   Meloni, G ^b   Petrucci, M T ^b   Spadea, A ^a   Redi, R ^b   Alimena, G ^b   Mandelli, F ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myelogenous leukemia; Hydroxyurea; MDR

Indexed keywords

CYTARABINE; FLUDARABINE; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY MRK 16; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ARTICLE; ASPERGILLUS; BONE MARROW APLASIA; CANCER RECURRENCE; CANCER REGRESSION; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE REARRANGEMENT; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; KARYOTYPE 46,XY; LIVER DISEASE; LUNG ASPERGILLOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; MUCOSA INFLAMMATION; MYELOID LEUKEMIA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRISOMY 8;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; GENES, MDR; HUMANS; HYDROXYUREA; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0041854628     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0693-2     Document Type: Article

References (18)

1. Nocentini G (1996) Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Hematol 22:89-126
2. Chabner BA, Allegra CJ, Curt GA, et al. (1996) Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman & Gilman's the phannacological basis of therapeutics, 9th edn. Mc Graw-Hill, New York, pp 1233-1287
3. Vaughan WP, Bierman PJ, Reed EC, Glenn LD, Kessinger A, Armitage JO (1992) High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent. Semin Oncol 19:110-115
4. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 91:1533-1541
5. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A (1984) Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute non lymphoblastic leukemia. Cancer Genet Cytogenet 11:332-350
6. Leith CP, Copecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biological subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 89:3323-3329
7. Von Hoff D, Van Devantes D, Forseth B, et al. (1990) Hydroxyurea can decrease gene copy numbers in tumor cell lines (abstract). Proc Am Assoc Cancer Res 31:378
8. Smith DC, Vaughan WP, Gwilt PR, Trump DL (1993) A phase I trial of high-dose continuous infusion of hydroxyurea. Cancer Chemother Pharmacol 33:139-143
9. Belt RJ, Haas CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 46:455-462
10. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchinson JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507-510
11. World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO offset publication 48. WHO, Geneva
12. Cuneo A, Bigoni R, Roberti MG, Bardi A, Rigolin GM, Piva N, Mancini M, Nanni M, Alimena G, Mecucci C, Matteucci C, La Starza R, Bernasconi P, Cavigliano P, Genini E, Zaccaria A, Testoni N, Carboni C, Castoldi G (1998) Detection and monitoring of trisomy 8 by fluorescence in situ hybridization in acute myeloid leukemia: a multicentric study Haematologica 83:21-26
13. Leith CP, Chen IM, Kopecky KY, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL (1995) Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR+/efflux- cases. Blood 86:2329-2342
14. Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin JL, de Cremoux P, Delvincourt C, Demour C, Drenou B, Fenneteau O, Feuillard J, Garnier-Suillerot A, Genne P, Gorisse MC, Gosselin P, Jouault H, Lacave R, Robert J (1997) Multicenter evaluation of the MDR phenotype in leukemia. Leukemia 11:1086-1094
15. Leith CP, Kopecky KY, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR Willman CL (1999) Frequency and clinical significance of the expression of the MDR protein MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study. Blood 94:1086-1099
16. Dalton WS, Durie BGM, Alberts DS, Gerlach JH, Cress AE (1986) Characterization of a new drug resistance human myeloma cell line that expresses p-glycoprotein. Cancer Res 46:5125-5130
17. Tafuri A, Sommaggio A, Burba L, Albergoni MP, Petrucci MT, Mascolo MG, Testi AM, Basso G (1995) Prognostic value of rhodamine-efflux and MDR1/P-gp 170 expression in childhood acute leukemia. Leuk Res 19:927-931
18. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903